PDE4 inhibitors 2001. Patent and literature activity 2000 - September 2001

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 1, 2002, Pages 93-112

  Norman, P ^a  

^a NONE   (United Kingdom)

Author keywords

Asthma; COPD; Dermatitis; Leukemia; PDE 4 inhibitor; Rheumatoid arthritis; TNF; Ulcerative colitis

Indexed keywords

3 (3 CYCLOPENTYLOXY 4 METHOXYBENZYL) 6 ETHYLAMINO 8 ISOPROPYL 3H PURINE; 4 (3 CHLOROPHENYL) 1,7 DIETHYLPYRIDO[2,3 D]PYRIMIDIN 2(1H) ONE; BAY 19 8004; BENZAMIDE DERIVATIVE; BRONCHODILATING AGENT; BYK 33043; CDC 801; CDC 998; CI 1044; CILOMILAST; CIPAMFYLLINE; D 4418; IC 485; KW 4490; MESOPRAM; N (3,5 DICHLORO 1 OXIDO 4 PYRIDINYL) 8 METHOXY 2 TRIFLUOROMETHYL 5 QUINOLINECARBOXAMIDE; NIK 616; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PUMAFENTRINE; ROFLUMILAST; ROLIPRAM; SH 636; THEOPHYLLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL STUDY; CONTROLLED STUDY; CROHN DISEASE; DERMATITIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG OXIDATION; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; MOUSE; NONHUMAN; PATENT; RAT; VOMITING;

EID: 0036140350     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.1.93     Document Type: Article

References (71)

1. PDE4 Inhibitors 1999
2. PDE4 Inhibitors
3. PDE4 inhibitors - A review of the recent patent literature
4. The Therapeutic Potential of PDE4 Inhibitors
5. Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents
6. Update on the therapeuticl potential of PDE4 inhibitors
7. The next generation of PDE4 inhibitors
8. Chronic obstructive pulmonary disease: Emerging therapies
9. Merrill Lynch Global Pharmaceutical Investor Conference
10. Cilomilast (Ariflo) 15 mg bid safety in a six month clinical trial program
11. Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast
12. An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers
13. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: A randomised, dose-ranging study
14. Cilomilast: A second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease
15. Cilomilast reduces the percentage of sputum neutrophils in patients with chronic obstructive pulmonary disease (COPD)
16. 3H]rolipram binding activity and their relationship to emetic behavior in the ferret
17. 1,4-cyclohexane-carboxylates: Potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma
18. Phosphodiesterase isozymes. Molecular targets for novel antiasthma agents
19. Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig
20. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis
21. Anti-inflammatory and immunomodulatory potential of the novel pde4 inhibitor roflumilast in vitro
22. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor
23. High oral absolute bioavailability of roflumilast, a new, orally active, once daily PDE4 inhibitor
24. Influence of food intake on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor
25. Development of master allergic mediators SMI Conference - Asthma: New Drug Targets & Innovative Therapeutics
26. Safety and efficacy of the new PDE4 inhibitor roflumilast administered to patients with exercise-induced asthma over 4 weeks
27. Acute anti-inflammatory effect of the novel phosphodiesterase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose
28. Bayer's pharmaceutical research strategy pays off: More than 40 substances in the pipeline - Development of asthma drug halted at Phase II - Submission of registration dossier for vardenafil scheduled for fall 2001
29. Molecular and cellular profile of the structurally novel phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004
30. The evaluation of a selective phosphodiesterase (PDE) 4 inhibitor, Bay 19-8004, in guinea-pig antigen challenge and ferret emesis models
31. The effect of an oral phosphodiesterase (PDE) 4 inhibitor Bay 19-8004 in primate asthma models
32. The Type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents
33. The profile of SCH351591, a novel phosphodiesterase 4 inhibitor
34. A novel phosphodiesterase Type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido [2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity
35. Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase Type 4 inhibitor
36. Effect of a novel anti-inflammatory compound, YM976, on antigen-induced eosinophil infiltration into the lungs in rats, mice, and ferrets
37. Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs
38. The selective phosphodiesterase 4 inhibitor CI-1044 (PD-189659) inhibits LPS-induced neutrophil recruitment and TNF-alpha release in rat airways
39. The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients
40. NIK-616, a new type of selective phosphodiesteraseIV (PDE IV) inhibitor with reduced emetic activity
41. Comparison of the PDE4 activities of Ariflo (SB 207499) with related 4-acetylenic substituted cyclohexyl alcohols and amines 221st ACS
42. Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-Dimethoxyphenyl)-2H-phthalazin-1-ones and analogues
43. Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones
44. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro [1,4]diazepino[6, 7,1-hi]indoles: Discovery of potent, selective phosphodiesterase Type 4 inhibitors
45. Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4] diazepino[6,7,1-hi]indoles: Novel PDE4 inhibitors
46. Substituted 4-(2,2-diphenylethyl)-pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters 221st ACS
47. Phenyl substituted analogs of CDP-840 as phosphodiesterase-4 inhibitors with improved potency, oral activity, and metabolic stability
48. 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: A potential treatment for asthma Bioorg
49. The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I
50. Phthalazine PDE4 inhibitors. II: The synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives
51. Phthalazine PDE4 inhibitors. Part 3: The synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor
52. Pharmacological characterization of Z15370A, a novel selective phosphodiesterase 4 inhibitor
53. Phthalazine PDE4 inhibitors. Part 3: The synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor
54. Synthesis and structure-activity relationship of N-arylrolipram derivatives as inhibitors of PDE4 isozymes
55. Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: A novel class of potent and selective phosphodiesterase Type 4D inhibitors
56. Synthesis of 4-(8-benzo-[1,2,5] oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid: A potent and selective phosphodiesterase Type 4D inhibitor
57. Disease activated drugs: A new concept for the treatment of asthma
58. Atomic structure of PDE4: Insights into phosphodiesterase mechanism and specificity
59. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis
60. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4
61. Conformational difference between PDE4 apoenzyme and holoenzyme
62. Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors
63. Hunting the emesis and efficacy targets of PDE4 inhibitors: Identification of the photoaffinity probe 8-(3-azidophenyl)-6-[(4-iodo-1H-1-imidazolyl) methyl]quinoline (APIIMQ)
64. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway
65. Emesis induced by inhibitors of Type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret
66. PDE4 cAMP-specific phosphodiesterases
67. Next generation respiratory disease therapeutics, an analysis of key competitor therapeutic pipelines
68. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D